With the increase in medications given EUA status for COVID, what is your process for receiving, monitoring, and communicating EUA updates and action items to involved staff? including regularly checking Fact Sheets and keeping EHR systems updated. Thank you!

With the increase in medications given EUA status for COVID, what is your process for receiving, monitoring, and communicating EUA updates and action items to involved staff? including regularly checking Fact Sheets and keeping the EHR systems updated. Thank you!

When you compound your chemotherapy preparations, do you account for overfill vs the final labeled volume?
1. Remove "estimated" volume of overfill.
2. Add "estimated" volume of overfill to the final volume on the label.
3. Pump bags to exact base fluid volume stated on the label.
4. Do not account for overfill in the final volume stated on the label.

Hi all -
For those centers that have Omnicell workstations in the OR, how do you display the medication concentration on the labels that print upon removal? Ideally we'd like to see the the quantity per total volume, followed in close proximity by quantity per milliliter enclosed by parentheses (quantity/mL). However, we have character and configuration limitations. Anesthesiology would prefer the display ox x mg/ml rather than the quantity per total volume.
Thanks-
Maria Cumpston, PharmD, CPPS
Medication Safety Officer
WVU Medicine

New recommendations allow for a second 50 mg IVP dose of alteplase in patients in cardiac arrest with known or high suspicion for PE, who had objective evidence response to the first alteplase 50 mg IVP dose but did not sustain ROSC. Pharmacy currently prepares the first 50 mg IVP, outside of our system ED locations, in a syringe as ready-to-administer with goal availability from request to delivery of <15 min.

New recommendations allow for a second 50 mg IVP dose of alteplase in patients in cardiac arrest with known or high suspicion for PE, who had objective evidence response to the first alteplase 50 mg IVP dose but did not sustain ROSC. Pharmacy currently prepares the first 50 mg IVP, outside of our system ED locations, in a syringe as ready-to-administer with goal availability from request to delivery of <15 min.

For any of the hospitals that converted to ENFit. What issues are you facing?
1. Are you having issues finding supplies?
2. Is your staff using the ENFit straws to draw up the medication or just drawing up directly into the syringe?
3. Are the straws used for each medication or do you save it for 24 hours?
4. Are you using the ENFit pouches to crush all medications or maybe just for HD medications?
5. Are you having issues where the connections are getting clogged more frequently?

Wondering who is using tamper resistant seals on oral liquid syringes? We prepare a lot of oral liquid doses for our pediatric patients and have historically used tamper resistant seals. New staff are saying they never used the seals at their previous institutions and questioning the practice, especially since we have a staffing shortage in peds. I consider using the seals as a best practice from a safety, product integrity, and diversion standpoint but interested in the practice at other institutions. Thank you for your thoughts and time.

Carol

We would like to know how you handle a patient that received Exparel(bupivacaine liposomal), went home and came back into the organization (ED, Ambulatory, Inpt) within 96 hours. Does your system alert them that the patient received Exparel within the last 96 hours?

We’d like to know how other organizations handle a patient that received Exparel, bupivacaine (liposomal), went home and came back into organization (ED, Ambulatory, Inpt) within 96 hours…does their system alert them that the patient received exparel within the last 96 hours?